ES2587863T3 - Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central - Google Patents
Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central Download PDFInfo
- Publication number
- ES2587863T3 ES2587863T3 ES12808401.9T ES12808401T ES2587863T3 ES 2587863 T3 ES2587863 T3 ES 2587863T3 ES 12808401 T ES12808401 T ES 12808401T ES 2587863 T3 ES2587863 T3 ES 2587863T3
- Authority
- ES
- Spain
- Prior art keywords
- inhibitor
- edema
- use according
- stroke
- inh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195254 | 2011-12-22 | ||
| EP11195254 | 2011-12-22 | ||
| US201261587371P | 2012-01-17 | 2012-01-17 | |
| US201261587371P | 2012-01-17 | ||
| PCT/EP2012/076691 WO2013093027A1 (en) | 2011-12-22 | 2012-12-21 | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2587863T3 true ES2587863T3 (es) | 2016-10-27 |
Family
ID=48667767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12808401.9T Active ES2587863T3 (es) | 2011-12-22 | 2012-12-21 | Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9452203B2 (OSRAM) |
| EP (1) | EP2793935B1 (OSRAM) |
| JP (1) | JP6127063B2 (OSRAM) |
| KR (1) | KR102022231B1 (OSRAM) |
| CN (1) | CN104080474B (OSRAM) |
| AU (1) | AU2012318275B2 (OSRAM) |
| CA (1) | CA2858984C (OSRAM) |
| DK (1) | DK2793935T3 (OSRAM) |
| ES (1) | ES2587863T3 (OSRAM) |
| WO (1) | WO2013093027A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210069016A1 (en) * | 2008-11-13 | 2021-03-11 | Gholam A. Peyman | Neurodegenerative Disorder Treatment Method |
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| SMT201700415T1 (it) | 2013-03-15 | 2017-11-15 | Shire Viropharma Inc | Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae) |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| WO2016081889A1 (en) * | 2014-11-21 | 2016-05-26 | Kurt Baekgaard Osther | Recombinant c1 esterase inhibitor and use thereof |
| HUE061076T2 (hu) | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Humanizált anti-C1s ellenanyagok alkalmazási eljárások |
| BR112018010160A8 (pt) * | 2015-11-19 | 2019-02-26 | Shire Human Genetic Therapies | inibidor da c1 esterase humana recombinante e usos do mesmo |
| DK3525583T3 (da) | 2016-10-12 | 2025-10-27 | Bioverativ Usa Inc | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| DE4244735A1 (de) | 1992-08-24 | 1994-03-31 | Behringwerke Ag | Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen |
| JP3941174B2 (ja) | 1996-08-26 | 2007-07-04 | 富士ゼロックス株式会社 | 複合材料及びその製造方法 |
| US7053176B1 (en) | 1999-09-16 | 2006-05-30 | Altana Pharma Ag | Combination of C1-INH and lung surfactant for the treatment of respiratory disorders |
| AU2001261024A1 (en) | 2000-04-12 | 2001-10-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| PT1965831E (pt) * | 2005-12-21 | 2011-10-19 | Pharming Intellectual Pty Bv | Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão |
| PL1965831T3 (pl) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego |
-
2012
- 2012-12-21 KR KR1020147020461A patent/KR102022231B1/ko active Active
- 2012-12-21 EP EP12808401.9A patent/EP2793935B1/en active Active
- 2012-12-21 JP JP2014548078A patent/JP6127063B2/ja active Active
- 2012-12-21 CA CA2858984A patent/CA2858984C/en active Active
- 2012-12-21 DK DK12808401.9T patent/DK2793935T3/en active
- 2012-12-21 AU AU2012318275A patent/AU2012318275B2/en active Active
- 2012-12-21 ES ES12808401.9T patent/ES2587863T3/es active Active
- 2012-12-21 WO PCT/EP2012/076691 patent/WO2013093027A1/en not_active Ceased
- 2012-12-21 CN CN201280063159.7A patent/CN104080474B/zh active Active
- 2012-12-21 US US14/364,097 patent/US9452203B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2793935T3 (en) | 2016-09-05 |
| EP2793935A1 (en) | 2014-10-29 |
| CA2858984C (en) | 2021-01-05 |
| JP6127063B2 (ja) | 2017-05-10 |
| US9452203B2 (en) | 2016-09-27 |
| CN104080474B (zh) | 2016-04-27 |
| WO2013093027A1 (en) | 2013-06-27 |
| KR20140107567A (ko) | 2014-09-04 |
| KR102022231B1 (ko) | 2019-09-19 |
| AU2012318275B2 (en) | 2016-05-19 |
| EP2793935B1 (en) | 2016-05-25 |
| US20140371425A1 (en) | 2014-12-18 |
| JP2015502389A (ja) | 2015-01-22 |
| AU2012318275A1 (en) | 2013-07-11 |
| CN104080474A (zh) | 2014-10-01 |
| HK1201729A1 (zh) | 2015-09-11 |
| CA2858984A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2587863T3 (es) | Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central | |
| US20090022704A1 (en) | Method for the treatment of gout or pseudogout | |
| KR101956585B1 (ko) | 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법 | |
| ES2804424T3 (es) | Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre | |
| ES2965937T3 (es) | Tratamiento para el plasminógeno de afecciones asociadas con la sobreexpresión de PAI-1 | |
| ES2886859T3 (es) | Terapia usando un inhibidor del factor xii en un trastorno neurotraumático | |
| US20200282024A1 (en) | Formulations for compound delivery | |
| EP3299382B1 (en) | Oligopeptide having proinflammatory cytokine secretion-inhibiting activity | |
| ES2646720T3 (es) | Composiciones y métodos para mejorar el pronóstico de un humano con hemorragia subaracnoidea | |
| US10751324B2 (en) | Treatment of TNF- alpha cytotoxicity | |
| JP6289511B2 (ja) | 羊水塞栓の治療剤 | |
| AU2005206159B2 (en) | Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension | |
| ES2351005B1 (es) | Uso de anhidrasa carbónica ii para la elaboración de un medicamento. | |
| ES2288524T3 (es) | Factor xiii en combinacion con factor ix para tratar la hemofilia b. | |
| HK1201729B (en) | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system | |
| KR102057454B1 (ko) | 수술 후 염증 반응 억제용 조성물 및 수술 후 인지 기능장애 예방용 또는 치료용 약학 조성물 | |
| CN103990147A (zh) | Toll作用蛋白（Tollip）在脑卒中疾病中的应用 | |
| JP2007262027A (ja) | Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤 |